BAI and ex vivo expanded Foxp3+ regulatory T cells were recently reported to be promising therapeutics strategy for SLE treatment since it was able to reduce Tfh cell differentiation, IL-21 production and mTOR activation while promote the differentiation of Foxp3+ regulatory T cell (Yang et al., 2019). This evidence concerns the gene FOXP3 and systemic lupus erythematosus.